Clear Sailing Likely for Victoza CV Indication

No might issues put forth for Tuesday FDA admonitory commission

Prcis records in push of an FDA admonitory board fittings Tuesday to reflect on adding an portent for GLP-1 inhibitor panacea liraglutide (Victoza) to alter the risk of remarkable adverse cardiovascular episodes in high-risk of maturities with species 2 diabetes tip ated teensy-weensy nicety with the patronage trial or computes.

Specifically, the broached indication for the glucagon-like peptide-1 (GLP-1) indistinct would be “as an adjunct to post treatment of cardiovascular probability factors to Remedy set the risk of big adverse cardiovascular sequels (cardiovascular decease, non-fatal myocardial infarction, or non-fatal rejections) in adults with species 2 diabetes mellitus and supreme cardiovascular jeopardy.”